Clinical Trials Directory

Trials / Completed

CompletedNCT03047954

Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Multicentre, Randomised, Double Blind, Placebo-controlled Study of the Efficacy and Safety of Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
179 (actual)
Sponsor
Vifor Pharma · Industry
Sex
All
Age
6 Months – 7 Years
Healthy volunteers
Not accepted

Summary

The objective of this pilot double-blind study was to evaluate the efficacy and the safety of Broncho-Vaxom 1 capsule (3.5 mg) per day for 9 months compared to placebo on the evolution of the disease in children suffering from Atopic Dermatitis (AD).

Detailed description

Children outpatients of both sexes, aged 6 months to 7 years, with AD confirmed by Haniffin-Rajka or Williams et al, and an AD score (SCORAD) between 25 and 70 were included and followed for 9 months. Patients were randomized to receive either Broncho-Vaxom 1 capsule (3.5 mg) per day or the corresponding placebo over 9 months. Children under general corticotherapy within one month of study start, patients with immunodeficiency, patient's affected body surface area less than 15% or greater than 70% or with known allergy to desonide were excluded. Outcome measures were a comparisons between the two groups in the number of AD flares during the study after the first month of treatment. Secondary outcome measures were comparisons between the two groups based on SCORAD evolution, area of eczema, amount of corticoids used and parents/investigator assessments.

Conditions

Interventions

TypeNameDescription
DRUGBroncho-VaxomBV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)
DRUGPlacebo - CapMatching Placebo capsule administered

Timeline

Start date
2003-07-01
Primary completion
2006-12-01
Completion
2006-12-01
First posted
2017-02-09
Last updated
2017-02-09

Source: ClinicalTrials.gov record NCT03047954. Inclusion in this directory is not an endorsement.